SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment o… Read more
SQZ Biotechnologies Company (SQZB) - Total Liabilities
Latest total liabilities as of September 2023: $27.91 Million USD
Based on the latest financial reports, SQZ Biotechnologies Company (SQZB) has total liabilities worth $27.91 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SQZ Biotechnologies Company - Total Liabilities Trend (2018–2022)
This chart illustrates how SQZ Biotechnologies Company's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SQZ Biotechnologies Company Competitors by Total Liabilities
The table below lists competitors of SQZ Biotechnologies Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WAYSIDE TECH GRP
MU:PYA
|
Germany | €284.27 Million |
|
Rover Metals Corp
OTCQB:ROVMF
|
USA | $709.26K |
|
Equity Story Group Ltd
AU:EQS
|
Australia | AU$2.69 Million |
|
Arqit Quantum Inc. Warrants
NASDAQ:ARQQW
|
USA | $15.62 Million |
|
Astron Paper & Board Mill Limited
NSE:ASTRON
|
India | ₹1.26 Billion |
|
KELLOGG - Dusseldorf Stock Exchang
DU:KEL
|
Germany | €12.01 Billion |
|
ESTEE LAUDER-A - Dusseldorf Stock Exchang
DU:ELAA
|
Germany | €16.23 Billion |
Liability Composition Analysis (2018–2022)
This chart breaks down SQZ Biotechnologies Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 14.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SQZ Biotechnologies Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SQZ Biotechnologies Company (2018–2022)
The table below shows the annual total liabilities of SQZ Biotechnologies Company from 2018 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $50.04 Million | -51.03% |
| 2021-12-31 | $102.18 Million | -1.70% |
| 2020-12-31 | $103.94 Million | +10.86% |
| 2019-12-31 | $93.76 Million | +77.95% |
| 2018-12-31 | $52.69 Million | -- |